Lytic Activity of CD8+ T-Cell Clone (P210) Against Leukemia Cells
| Patient . | b3a2 . | b2a2 . | Sample . | HLA . | Ph1 Positivity % . | Lytic Activity (%) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia Cells . | CD3+ PHA Blasts . | ||||||||||
| A . | B . | DR . | IFN(−) . | IFN(+) . | IFN(−) . | IFN(+) . | |||||
| AS | + | − | PB | 2402 | 4006/1518 | 0406/1101 | 100 | 66 ± 3 | 80 ± 6 | 0 | 1 |
| HM | + | − | BM | 2402/3303 | 5401/3501 | 0406/0410 | 100 | 51 ± 5 | 46 ± 4 | 0 | 0 |
| SA | + | + | BM | 2402/0201 | 4403/5401 | 0405/1302 | 100 | 27 ± 3 | 44 ± 5 | NT | NT |
| AM | + | − | BM | 2402/0301 | 4402/5401 | 0403/1301 | 96 | 14 ± 2 | 20 ± 3 | 1 | 1 |
| FS | + | − | PB | 1101/3101 | 5101/1501 | 0406/0802 | 32 | 17 ± 2 | 36 ± 4 | 0 | 1 |
| MW | + | − | PB | 0201/2902 | 4403/5101 | 0407/0701 | 83 | 28 ± 3 | 36 ± 3 | 0 | 0 |
| KT | + | − | BM | 0201/2603 | 0702/4403 | 0101/1302 | 90 | 11 ± 2 | 21 ± 3 | NT | NT |
| BC | − | + | PB | 0301 | 3501 | 0101 | 50 | 4.0 ± 0.4 | 3.0 ± 1.2 | NT | NT |
| JA | − | + | PB | 2402/0301 | 0702/1402 | 0102/0701 | 100 | 2.1 ± 0.4 | 3.7 ± 0.0 | NT | NT |
| AO | − | + | PB | 2402/0201 | 0801/4402 | 0301/0401 | 30 | 1.2 ± 0.9 | 1.7 ± 0.4 | NT | NT |
| KP | − | + | PB | 0301 | 2703/3501 | 0404 | 25 | 2.4 ± 0.3 | −3.6 ± 2.1 | NT | NT |
| Patient . | b3a2 . | b2a2 . | Sample . | HLA . | Ph1 Positivity % . | Lytic Activity (%) . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Leukemia Cells . | CD3+ PHA Blasts . | ||||||||||
| A . | B . | DR . | IFN(−) . | IFN(+) . | IFN(−) . | IFN(+) . | |||||
| AS | + | − | PB | 2402 | 4006/1518 | 0406/1101 | 100 | 66 ± 3 | 80 ± 6 | 0 | 1 |
| HM | + | − | BM | 2402/3303 | 5401/3501 | 0406/0410 | 100 | 51 ± 5 | 46 ± 4 | 0 | 0 |
| SA | + | + | BM | 2402/0201 | 4403/5401 | 0405/1302 | 100 | 27 ± 3 | 44 ± 5 | NT | NT |
| AM | + | − | BM | 2402/0301 | 4402/5401 | 0403/1301 | 96 | 14 ± 2 | 20 ± 3 | 1 | 1 |
| FS | + | − | PB | 1101/3101 | 5101/1501 | 0406/0802 | 32 | 17 ± 2 | 36 ± 4 | 0 | 1 |
| MW | + | − | PB | 0201/2902 | 4403/5101 | 0407/0701 | 83 | 28 ± 3 | 36 ± 3 | 0 | 0 |
| KT | + | − | BM | 0201/2603 | 0702/4403 | 0101/1302 | 90 | 11 ± 2 | 21 ± 3 | NT | NT |
| BC | − | + | PB | 0301 | 3501 | 0101 | 50 | 4.0 ± 0.4 | 3.0 ± 1.2 | NT | NT |
| JA | − | + | PB | 2402/0301 | 0702/1402 | 0102/0701 | 100 | 2.1 ± 0.4 | 3.7 ± 0.0 | NT | NT |
| AO | − | + | PB | 2402/0201 | 0801/4402 | 0301/0401 | 30 | 1.2 ± 0.9 | 1.7 ± 0.4 | NT | NT |
| KP | − | + | PB | 0301 | 2703/3501 | 0404 | 25 | 2.4 ± 0.3 | −3.6 ± 2.1 | NT | NT |
Lytic activity of CD8+ cell clone (P210) is shown against leukemia cells from patients with chronic-phase CML and PHA blasts before (IFN−) and after (IFN+) incubation with IFN.